Maximizing the Natriuretic Peptide System in Experimental Heart Failure | Zendy

Horng H. Chen | Zendy; John G. Lainchbury | Zendy; Gail J. Harty | Zendy; John C. Burnett | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maximizing the Natriuretic Peptide System in Experimental Heart Failure

Author(s) -

Horng H. Chen,

John G. Lainchbury,

Gail J. Harty,

John C. Burnett

Publication year - 2002

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/hc0802.104282

Subject(s) - medicine , heart failure , natriuretic peptide , brain natriuretic peptide , cardiology , endocrinology

A hallmark of congestive heart failure (CHF) is the elevation of the cardiac natriuretic peptides (NPs), which have natriuretic, renin-inhibiting, vasodilating, and lusitropic properties. We have reported that chronic subcutaneous (SQ) administration of brain natriuretic peptide (BNP) in experimental CHF improves cardiorenal function. Vasopeptidase inhibitors (VPIs) are single molecules that simultaneously inhibit both neutral endopeptidase 24.1 (NEP) and ACE. We hypothesized that acute VPI administration would potentiate the cardiorenal actions of SQ BNP in experimental CHF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research